{"id":110,"date":"2014-01-20T18:06:39","date_gmt":"2014-01-20T18:06:39","guid":{"rendered":"https:\/\/ananyajainblog.wordpress.com\/2014\/01\/20\/merk-thankful-to-us-fda-for-approval-of-vorapaxar"},"modified":"2016-10-29T21:52:29","modified_gmt":"2016-10-29T21:52:29","slug":"merk-thankful-to-us-fda-for-approval-of-vorapaxar","status":"publish","type":"post","link":"http:\/\/www.jainananya.com\/blog\/2014\/01\/20\/merk-thankful-to-us-fda-for-approval-of-vorapaxar\/","title":{"rendered":"Merk Thankful to US FDA for approval of Vorapaxar"},"content":{"rendered":"<p>Vorapaxar is the company\u2019s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.<\/p>\n<p>\u201cThere are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have a recurrent heart attack, so there remains a need for additional treatment options,\u201d said Dr. Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. \u201cThe results of today\u2019s Advisory Committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack. We look forward to working with the FDA as it completes its review.\u201d<\/p>\n<p>Vorapaxar\u2019s trade name is proposed to be registered as Zontivity<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vorapaxar is the company\u2019s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. \u201cThere are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have&#8230;<\/p>\n","protected":false},"author":1,"featured_media":233,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[11],"class_list":["post-110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-httpwww-drugs-comndazontivity_140115-html"],"_links":{"self":[{"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/posts\/110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/comments?post=110"}],"version-history":[{"count":1,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/posts\/110\/revisions"}],"predecessor-version":[{"id":249,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/posts\/110\/revisions\/249"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/media\/233"}],"wp:attachment":[{"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/media?parent=110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/categories?post=110"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.jainananya.com\/blog\/wp-json\/wp\/v2\/tags?post=110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}